A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney functionHiddo J.L. Heerspink, Dánae Duana Ávila, Douwe Postmus et al.|Kidney International|2021Cited by 95